P&T Committee Meeting Minutes

| Subject: | Louisiana Department of Health and Hospitals  
Medicaid Pharmaceutical and Therapeutic Committee Meeting |
|---------|-------------------------------------------------------|
| Location: | 628 North Fourth Street  
Baton Rouge, LA  
Bienville Building  
Room 118 |
| Date: | November 2, 2016 |
| Members Present: | Harold Brandt, MD  
Jeff Deyo, MD  
Martha Harris, PharmD  
James Lu, MD  
Ed Mader, MD  
Catherine McDonald, MD  
Fred Mills (Senator)  
Ben Orlando  
J. Rogers Pope (Representative)  
Neil Wolfson, MD  
Marty R. McKay, RPh |
| DHH Pharmacy Program Staff Present: | Melwyn Wendt, RPh  
Germaine Becks-Moody, PhD, BHSF Program Manager  
Sue Fontenot, RPh  
Paul Knecht, RPh  
Kim Sullivan  
SreyRam Kuy, MD, MHS |
| Contractors Present: | Nina Bandali, PharmD, Magellan Medicaid Administration  
Jennifer Picket, Certified Court Reporter |
| Others Present: | Presenters are listed in the minutes and sign in sheets and others in attendance from DHH, Bureau of Health Services Financing, Pharmacy Benefits Section upon request. |

Opening Remarks

While waiting on a quorum, Dr. SreyRam Kuy, presented “The Opioid Crisis Symposium.” She felt it was important to spend some time on the opioid crisis situation in the U.S. Sales of prescription opioids in the U.S. quadrupled from 1999 to 2014. In 2012, 259 million prescriptions were written
for opioid pain medication in the U.S. Typically, abuse starts with prescription drugs. In 2013, Louisiana ranked first in the U.S. for proportion of opioids prescribed per capita among all 50 states. The number of overdose deaths outnumber motor vehicle deaths. Top sources for prescription painkillers were friends or family.

What is Louisiana Medicaid currently doing to combat opioid abuse?

- Non-opioid Pain Treatment Options
- Substance Abuse Rehab
- Pharmacy “Lock-In” Program
- Pharmacy Monitoring Program (PMP)
- Prevention of Prescription Duplication
- Prevention of Early Refills
- Substance Use Disorder Prescription Benefits

These are great first steps, but not enough. Louisiana leads the U.S. in this opioid epidemic. We need to learn others’ successful strategies, for example, the State of Washington decreased opioid overdose deaths by 37%. This was done by the following:

- Opioid Limits*
- Opioid Dosing Guidelines*
- Collaboration between agencies*
- Pain Conference*
- Prescription Monitoring Program*
- Education for providers (free CME, dose calculators, websites)
- Metrics for tracking outcomes and progress
- Incentivized non-opioid alternatives

*Already or Planned Adoption by Louisiana Medicaid

How do we proceed next? Dr. Tom Frieden, CDC Director, stated “The prescription overdose epidemic is doctor-driven. It can be reversed in part by doctors.”

Future Medicaid strategies consist of the following:

- Opioid prescription quantity limits (staged implementation) for adults and children discussed at the Pharmacy Drug & Utilization Review Board on September 21, 2016. There will be certain exemptions for cancer, palliative care, and terminal illnesses.
- Clinical pre-authorization for long-acting opioids
• Guidelines on opioid dosing threshold based on morphine-equivalence
• Initiate coverage of Medication Assisted Therapy (MAT)/methadone coverage
• Reduce “red tape” for provider by automation of over-rides and exemptions

Dr. Kuy thanked everyone for the time spent on this very serious epidemic. She emphasized that together we can make Louisiana healthier and safer.

Call to Order

Marty R. McKay, Chairman, called the meeting to order at 9:57 a.m. after a quorum was reached with 11 members. He stated that this meeting will be conducted in compliance with the Open Meetings Law.

Parliamentary Business

A. Introduction of Members. A Committee members and staff introduce themselves.

B. Additional Agenda Items. The Chair entertained requests for additional agenda items. Mr. Orlando moved to add the class Ophthalmic Antibiotic/Steroid Combinations as number 58 on the agenda. The motion was seconded by Dr. Wolfson. Mr. McKay explained that the reason this was added that it was omitted from the agenda. A roll call vote was taken: all affirmative and no objections. Mr. McKay called for public comment on any non-agenda items. Hearing none, Mr. McKay continued on with the business on hand.

C. Approval of Minutes. Mr. McKay asked for a motion to approve the minutes from May 4, 2016. There were no objections to approving the minutes. Mr. McKay asked for a motion to reorder the agenda as necessary. There were no objections.

Ethics Reminder

Code of Ethics. Ms. Sullivan went over the code of ethics. Members are bound by the governmental code of ethics. She suggested for all to go to the Board’s website, http://www.ethics.state.la.us, for webinars. If anyone has personal ethical questions, please contact Kim Sullivan at Kimberly.sullivan@la.gov.

Reports

A. Melwyn Wendt from DHH provides report. Ms. Wendt stated that the list of prior authorizations, the monthly report that was there for the fee-for-service claims and the PDL list were all included in the packet.

New Business

A. Therapeutic Class Reviews of Drug Classes/Drug Manufacturer Testimony

In accordance with state law and the P&T Committee’s bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee’s review.
<table>
<thead>
<tr>
<th>Presenter</th>
<th>Representing</th>
<th>Drug/Issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Cant</td>
<td>Allergan</td>
<td>Namzaric, Vraylar</td>
</tr>
<tr>
<td>Michael Barber</td>
<td>Sunovion</td>
<td>Latuda</td>
</tr>
<tr>
<td>Jason Swartz</td>
<td>Otsuka</td>
<td>Rexulti</td>
</tr>
<tr>
<td>Vicki Ryan</td>
<td>Mental Health America of Louisiana</td>
<td>Medications for mental illness</td>
</tr>
<tr>
<td>Richard Fiscella</td>
<td>Allergan</td>
<td>Lumigan</td>
</tr>
<tr>
<td>Corey Hebert</td>
<td>Rhodes Pharma</td>
<td>Aptensio XR</td>
</tr>
<tr>
<td>Pat Trifunov</td>
<td>Tris Pharma</td>
<td>Dyanavel XR</td>
</tr>
<tr>
<td>George Kehner</td>
<td>Neos Therapeutics</td>
<td>Adzenys XR ODT</td>
</tr>
</tbody>
</table>

**NOTE:** Names of speakers who were present and yielded their time back were not captured.

**Alzheimer’s Agents**

Mr. Orlando makes the motion to accept. Dr. Mader seconds the motion. Dr. Brandt asked the speaker if the cost of care of the combination of the dual drugs of Namzaric would be lower per month than the two combined generics. Mr. Cant did not have such data. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Donepezil ODT
- Donepezil tablet
- Exelon
- Memantine tablet, tablet dose pack

**Antidepressants, Other**

Dr. Wolfson makes the motion to accept. Mr. Orlando seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- All forms of generic buproprion and buproprion SR
- Mirtazapine and ODT
- Pristiq
- Trazodone
- Venlafaxine
- Venlafaxine ER capsule

**Antidepressants, SSRI**

Mr. Orlando makes the motion to accept. Dr. McDonald seconds the motion. There was no objection to the motion.
Committee recommendations for the PDL are:

- Citalopram tab and soln
- Escitalopram tab
- Fluoxetine caps, soln
- Fluvoxamine
- Paroxetine tab
- Sertraline tab and soln

**Antihistamines, Minimally Sedating**

Dr. Wolfson makes the motion to accept. Mr. Orlando seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Cetirizine
- Levocetirizine
- Loratadine

**Antihypertensives, Sympatholytics**

Mr. Orlando makes the motion to accept. Dr. Harris seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Catapres-TTS patch
- Clonidine generic
- Guanfacine
- Methyldopa

**Antihyperuricemics**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Allopurinol
- Probenecid
- Probenecid combination with colchicine
Antiparkinson’s Agents

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Amantadine
- Benztropine
- Carbidopa/levodopa
- Carbidopa/levodopa ER
- Carbidopa/levodopa/entacapone
- Pramipexole
- Ropinirole
- Selegiline tab/cap
- Trihexyphenidyl tab/elixir

Antipsoriatrics, Oral

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Acitretin

Antipsoriatrics, Topical

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Calcipotriene cream, ointment, and solution

Antipsychotics

Dr. Brandt asked if additional consideration can be given to the generic aripiprazole. There was a motion on the floor by Mr. Orlando and seconded by Dr. Wolfson. Mr. McKay asked if Magellan had considered the generic since the price is dropping out. Dr. Bandali responded that other cost-effective agents are available, and aripiprazole can be obtained with a prior authorization (PA) that is rather easy to get. Dr. Brandt stated he sees people who are suicidal to no longer suicidal in a matter of four days because of aripiprazole. Dr. Brandt offered a substitute motion; seconded by Mr. Orlando. Dr. McDonald felt it was a good idea to add aripiprazole. A vote was taken to add aripiprazole to the PDL.
Dr. McDonald didn't feel that Latuda needed to be added. Dr. Wolfson questioned if it really does take 2 days for a PA. Ms. Wendt stated that PAs are handled by the University of Louisiana at Monroe for fee-for-service, and a PA request must be turned around in 24 hours, most of which are completed faster than 24 hours. Senator Mills asked how many denials take place on PA requests. Ms. Wendt stated the percentage of denials is very small especially when there is justification for the drug. Dr. Brandt commented on the sheer magnitude of PAs that his office sees. Ms. Wendt stated that there are 5 MCOs, and they too must turn around a PA in 24 hours. Further discussion ensued on filling emergency supplies if Medicaid was closed to approve the PA.

There were no objections to the motion to add aripiprazole.

**Committee recommendations for the PDL are:**

- Abilify Maintena
- Amitriptyline/perphenazine oral
- Aripiprazole tab
- Aristada
- Chlorpromazine oral
- Clozapine oral
- Fluphenazine tab/inj
- Geodon IM
- Haloperidol lactate conc/oral/inj
- Haloperidol decanoate inj
- Invega Sustenna
- Invega Trinza
- Loxapine oral
- Olanzapine tab/ODT
- Orap
- Perphenazine oral
- Quetiapine oral
- Risperdal Consta inj
- Risperidone tab/soln
- Seroquel XR
- Thioridazine oral
- Thiothixene oral
- Trifluoperazine oral
- Ziprasidone cap

**Anxiolytics**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

**Committee recommendations for the PDL are:**

- buspirone
- lorazepam

**Bile Salts**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

**Committee recommendations for the PDL are:**
• Ursodiol tablet

**Bronchodilators, Beta Agonist**

Dr. Wolfson makes the motion to accept. Dr. McDonald seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Albuterol nebulizer solutions – all strengths
• Albuterol tab/syrup
• ProAir HFA
• Proventil HFA
• Serevent
• Terbutaline oral

**COPD Agents**

Mr. Orlando makes the motion to accept. Dr. Harris seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Atrovent HFA
• Combivent Respimat
• Ipratropium/Albuterol combination nebulizer
• Ipratropium nebulizer
• Spiriva

**Cytokine and CAM Antagonists**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. Dr. Deyo asked for a comment on Enbrel being nonpreferred. Dr. Bandali pointed out the utilization and the consideration of clinical and financial data. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Cosentyx
• Humira

**Emollients**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*
• Ammonium lactate cream/lotion
• Lactic Acid cream/lotion

**Epinephrine, Self-Injected – new class for review**

Mr. Orlando asked if there were any quantity limits on these agents. Ms. Wendt responded that there were no limits for fee-for-service but can be brought up in the drug utilization review. Mr. Orlando makes the motion to accept. Dr. Harris seconds the motion. Thereafter, discussion took place on the availability of the generic as well as the pricing differential between brand and generic; also, no substitution for the generic being allowed if the prescription was written for the brand. The discussion continued on the cost impact to the class if the brand was made nonpreferred. Dr. Wolfson stressed that every effort should be made to get the generic due to this abusive situation. There was no objection to the motion to add both the brand and generic.

*Committee recommendations for the PDL are:*

• Epinephrine (generic for Adrenaclink)
• Epipen

**Erythropoiesis Stimulating Proteins**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Aranesp
• Procrin

**Glucocorticoids, Inhaled**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Advair Diskus
• Asmanex
• Dulera
• Pulmicort Respules 0.25 mg, 0.5 mg, 1 mg
• Qvar
• Symbicort

**Histamine II Receptor Blockers**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.
Committee recommendations for the PDL are:

- Famotidine tabs
- Ranitidine syrup and tabs

**Immunomodulators, Atopic Dermatitis**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Elidel

**Immunomodulators, Topical**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Imiquimod

**Intranasal Rhinitis Agents**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Fluticasone
- Ipratropium nasal
- Patanase

**Leukotriene Modifiers**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Montelukast tab/chew tab

**Neuropathic Pain**

Dr. Wolfson makes the motion to accept. Mr. Orlando seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Duloxetine
• Gabapentin caps/tab
• Lidocaine patch
• Neurontin solution

**NSAIDS**

Mr. Orlando makes the motion to accept. Dr. Mader seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Diclofenac sodium and SR
- Ibuprofen tab and susp
- Indocin susp
- Indomethacin caps
- Ketorolac
- Meloxicam tab and susp
- Nabumetone
- Naproxen tab, susp and naproxen EC
- Sulindac
- Voltaren topical gel

**Ophthalmic Antibiotic/Steroid Combinations**

Mr. Orlando makes the motion to accept. Dr. Harris seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Neomycin/polymyxin B/Dexamethasone combination
- Sulfacetamide/Prednisolone combination
- TobraDex ointment and suspension

**Ophthalmic Antibiotics**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.
Committee recommendations for the PDL are:

- Bacitracin/polymyxin B sulfate oint
- Bleph-10
- Ciprofloxacin soln
- Erythromycin
- Gentamicin drops/ointment
- Ilotycin

- Moxeza
- Neomycin/polymyxin/gramicidin
- Ofloxacin
- Polymyxin/trimethoprim
- Sulfacetamide soln
- Tobramycin
- Vigamox

**Ophthalmics, Anti-Inflammatory/Immunomodulator – new class for review**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Restasis

**Ophthalmics for Allergic Conjunctivitis**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Alrex
- Cromolyn
- Olopatadine
- Pataday
- Pazeo

**Ophthalmic Anti-inflammatories**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Dexamethasone
- Diclofenac
- Durezol
- Fluorometholone
- Flurbiprofen
- Ilevro
- Ketorolac and LS

**Ophthalmics, Glaucoma Agents**

Dr. Wolfson makes the motion to accept. Dr. Orlando seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Alphagan P 0.15%
- Brimonidine
- Carteolol
- Combigan
- Dorzolamide and Dorzolamide/timolol
- Latanoprost 2.5 mL
- Levobunolol
- Pilocarpine
- Simbrinza
- Timolol
- Travatan-Z

**Otic Anti-infectives & Anesthetics**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Acetic Acid
- Acetic Acid HC

**Otic Antibiotics**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Ciprodex
- Neomycin/Polymyxin/Hydrocortisone solution/suspension

**Progestational Agents**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Makena MDV & SDV
Sedative Hypnotics

Mr. Orlando makes the motion to accept. Dr. McDonald seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Temazepam
- Triazolam
- Zolpidem

Smoking Cessation

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. Dr. Wolfson asked about the large settlement made in the tobacco case that affected Louisiana residents. Dr. Brandt responded that the settlement is limited to people who started smoking prior to 1988. They will have full coverage from the trust settlement. Dr. Wolfson emphasized that physicians should be educated and take advantage of this. He expressed his concern as to why Medicaid should pay for the same thing that a settlement has already been made for. Senator Mills suggested reaching out to the trust expansion funds and partnering with the trust to see what opportunities are out there. He recommended a report back to the Committee. There was no objection to the motion.

Committee recommendations for the PDL are:

- Bupropion SR
- Chantix and Chantix Dose Pack
- Nicotine gum, patch

Steroids Topical, High Potency

Dr. Wolfson makes the motion to accept. Mr. Orlando seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Betamethasone dipropionate/prop gly cream
- Betamethasone valerate cream/lotion/ointment
- Triamcinolone acetonide cream/lotion/ointment

Steroids Topical, Low Potency

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- Alclometasone dipropionate cream/ointment
- Hydrocortisone cream/lotion/ointment
Hydrocortisone/mineral oil/petrolatum combination

**Steroids Topical, Medium Potency**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Fluticasone propionate ointment/cream
- Hydrocortisone butyrate soln
- Mometasone furoate cream/ointment/soln
- Prednicarbate cream

**Steroids Topical, Very High Potency**

Dr. Wolfson makes the motion to accept. Mr. Orlando seconds the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Clobetasol emollient
- Clobetasol propionate cream, gel, oint, soln
- Halobetasol cream/ointment

**Stimulants and Related Agents**

Mr. Orlando makes the motion to accept. Dr. Wolfson seconds the motion. Dr. Mader questioned why Provigil and Nuvigil were not recommended. Further discussion took place on which product to add. There was an amended motion to add modafinil. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- Adderall XR
- Amphetamine Salt Combo Immediate Release
- Dextroamphetamine
- Dextroamphetamine
- Focalin XR
- Guanfacine ER
- Metadate CD
- Methylphenidate IR and ER (generic for Concerta)
- Modafinil
- ProCentra
- Quillichew ER
• Quillivant XR
• Strattera
• Vyvanse

II. Single Drugs

The new drug reviews or single drug reviews are on products that have come to the market since the last review of the class.

In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

<table>
<thead>
<tr>
<th>Presenter</th>
<th>Representing</th>
<th>Drug/Issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher Cant</td>
<td>Allergan</td>
<td>Byvalson</td>
</tr>
</tbody>
</table>

**NOTE**: Names of speakers who were present and yielded their time back were not captured.

The single drugs were reviewed and a recommendation was made. P&T Committee recommendations follow:

**Angiotensin Modulator Combinations**

Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer Byvalson

**Angiotensin Modulators**

Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer Qbrelis

**Analgesics, Narcotics Long**

Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer Xampza ER
Antiemetic/Antivertigo Agents
Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*
  - Non-prefer Emend Powder Packet

Antifungals, Topical
Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*
  - Non-prefer Loprox Kit

Antimigraine Agents, Triptans
Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*
  - Non-prefer Onzetra Xsail
  - Non-prefer Zembrace Symtouch
  - Non-prefer Migranow Kit

GI Motility, Chronic
Mr. Orlando made the motion to accept. Dr. McDonald seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*
  - Non-prefer Relistor

Hepatitis C
Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. Mr. McKay asked the Department for their thoughts. Ms. Wendt stated that they are in agreement with Magellan's recommendations. The Department has had extensive conversations with Magellan. Dr. Bandali commented that this is a class that is closely watched by Magellan. There was no objection to the motion.

*Committee recommendations for the PDL are:*
  - Prefer Viekira XR
• Prefer Epclusa for genotypes 2 & 3 only

**Hypoglycemics, Incretin Mimetics/Enhancers**

Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer Jentadueto XR

**Lipotropics, Other**

Mr. Orlando made the motion to accept. Dr. Mader seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer Repatha Pushtronex

**Multiple Sclerosis Agents**

Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer Zinbryta

**Opiate Dependence Treatment**

Mr. Orlando made the motion to accept. Dr. Wolfson seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer Probuphine

**Tetracyclines**

Mr. Orlando made the motion to accept. Dr. Deyo seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

• Non-prefer Doryx MPC

**Other Business**

None

**Proposed Therapeutic Classes to be Reviewed at Next Meeting**
Therapy classes to be reviewed for the April 2017 meeting will be posted on the DHH Medicaid Pharmacy and Therapeutics Committee page as “Agenda.”

**Next Meeting Date**

The next committee meeting is scheduled for April 26, 2017. Mr. McKay requested that the members go back and look at their calendars.

**Adjournment**

The meeting adjourned at 12:06 p.m

Marty R. McKay, R.Ph
Chairman, P&T Committee Meeting